1. Home
  2. ZURA vs IHRT Comparison

ZURA vs IHRT Comparison

Compare ZURA & IHRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zura Bio Limited

ZURA

Zura Bio Limited

HOLD

Current Price

$4.51

Market Cap

455.4M

Sector

Health Care

ML Signal

HOLD

Logo iHeartMedia Inc.

IHRT

iHeartMedia Inc.

HOLD

Current Price

$2.39

Market Cap

589.5M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZURA
IHRT
Founded
2022
1974
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Broadcasting
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
455.4M
589.5M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
ZURA
IHRT
Price
$4.51
$2.39
Analyst Decision
Buy
Sell
Analyst Count
6
2
Target Price
$13.00
$4.25
AVG Volume (30 Days)
1.8M
424.8K
Earning Date
05-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
54.19
EPS
N/A
N/A
Revenue
N/A
$3,864,991,000.00
Revenue This Year
N/A
$9.96
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
0.27
52 Week Low
$2.01
$2.32
52 Week High
$7.25
$6.56

Technical Indicators

Market Signals
Indicator
ZURA
IHRT
Relative Strength Index (RSI) 33.11 32.35
Support Level $4.36 N/A
Resistance Level $5.87 $2.90
Average True Range (ATR) 0.35 0.13
MACD -0.14 -0.00
Stochastic Oscillator 9.71 15.52

Price Performance

Historical Comparison
ZURA
IHRT

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

About IHRT iHeartMedia Inc.

iHeartMedia Inc is a United States-based audio media company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.

Share on Social Networks: